Qurient Co Ltd
115180
Company Profile
Business description
Qurient Co Ltd is a South Korea based biotech company. It is engaged in network research & development business model, integrating research and drug development programs with a new mechanism. Its pipeline products include Q301 for the treatment of atopic dermatitis; Q203 treats MDR/XDR/TDR TB, and Q701 is a drug-resistant cancer immuno-oncology.
Contact
C-dong 8th Floor, 242, Pangyo-ro
Bundang-gu
Seongnam-siGyeonggi-do13487
KORT: +82 3180601600
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
32
Stocks News & Analysis
stocks
AI driving growth for ASX tech share
ASX tech share raises funds to facilitate customer AI spend.
stocks
OpenAI is going public as the worst value among its peers
Investors are paying a steep price relative to the underlying business quality, PitchBook research says.
stocks
Wide moat healthcare leader remains undervalued
ASX healthcare giant expected to see uptick in demand from emerging markets.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,824.80 | 67.50 | 0.77% |
| CAC 40 | 8,203.43 | 4.14 | 0.05% |
| DAX 40 | 24,433.06 | 183.16 | -0.74% |
| Dow JONES (US) | 50,702.09 | 83.92 | -0.17% |
| FTSE 100 | 10,227.33 | 145.87 | -1.41% |
| HKSE | 24,565.90 | 91.16 | -0.37% |
| NASDAQ | 25,471.73 | 457.93 | -1.77% |
| Nikkei 225 | 65,416.63 | 1,392.03 | 2.17% |
| NZX 50 Index | 13,204.08 | 165.84 | 1.27% |
| S&P 500 | 7,339.36 | 66.37 | -0.90% |
| S&P/ASX 200 | 8,604.20 | 70.70 | 0.83% |
| SSE Composite Index | 4,010.03 | 50.69 | 1.28% |